JP2016511256A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016511256A5 JP2016511256A5 JP2015560296A JP2015560296A JP2016511256A5 JP 2016511256 A5 JP2016511256 A5 JP 2016511256A5 JP 2015560296 A JP2015560296 A JP 2015560296A JP 2015560296 A JP2015560296 A JP 2015560296A JP 2016511256 A5 JP2016511256 A5 JP 2016511256A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cancer
- epas1
- nucleotides
- antisense strand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims description 51
- 201000010099 disease Diseases 0.000 claims description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
- 108091030071 RNAI Proteins 0.000 claims description 33
- 230000009368 gene silencing by RNA Effects 0.000 claims description 33
- 102100036448 Endothelial PAS domain-containing protein 1 Human genes 0.000 claims description 32
- 108010018033 endothelial PAS domain-containing protein 1 Proteins 0.000 claims description 32
- 239000003795 chemical substances by application Substances 0.000 claims description 29
- 125000003729 nucleotide group Chemical group 0.000 claims description 28
- 239000002773 nucleotide Substances 0.000 claims description 26
- 230000000692 anti-sense effect Effects 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 108091081021 Sense strand Proteins 0.000 claims description 14
- 206010027476 Metastases Diseases 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 6
- 206010003571 Astrocytoma Diseases 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 6
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 6
- 206010029260 Neuroblastoma Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 6
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 230000002491 angiogenic effect Effects 0.000 claims description 6
- 208000037976 chronic inflammation Diseases 0.000 claims description 6
- 230000006020 chronic inflammation Effects 0.000 claims description 6
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 208000007565 gingivitis Diseases 0.000 claims description 6
- 208000005017 glioblastoma Diseases 0.000 claims description 6
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 201000010982 kidney cancer Diseases 0.000 claims description 6
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 230000009401 metastasis Effects 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 claims description 6
- 206010038038 rectal cancer Diseases 0.000 claims description 6
- 201000001275 rectum cancer Diseases 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 201000011461 pre-eclampsia Diseases 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- 102000004856 Lectins Human genes 0.000 claims description 2
- 108090001090 Lectins Proteins 0.000 claims description 2
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 claims description 2
- 101710163270 Nuclease Proteins 0.000 claims description 2
- 229920001218 Pullulan Polymers 0.000 claims description 2
- 239000004373 Pullulan Substances 0.000 claims description 2
- 102000004338 Transferrin Human genes 0.000 claims description 2
- 108090000901 Transferrin Proteins 0.000 claims description 2
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000003431 cross linking reagent Substances 0.000 claims description 2
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 claims description 2
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
- 239000002523 lectin Substances 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 150000002634 lipophilic molecules Chemical class 0.000 claims description 2
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229920005615 natural polymer Polymers 0.000 claims description 2
- 238000011580 nude mouse model Methods 0.000 claims description 2
- 239000000816 peptidomimetic Substances 0.000 claims description 2
- 229920000768 polyamine Polymers 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 235000019423 pullulan Nutrition 0.000 claims description 2
- 125000006853 reporter group Chemical group 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 150000003505 terpenes Chemical class 0.000 claims description 2
- 235000007586 terpenes Nutrition 0.000 claims description 2
- 239000012581 transferrin Substances 0.000 claims description 2
- 150000003648 triterpenes Chemical class 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 230000004048 modification Effects 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361770713P | 2013-02-28 | 2013-02-28 | |
| US61/770,713 | 2013-02-28 | ||
| PCT/US2014/018873 WO2014134255A2 (en) | 2013-02-28 | 2014-02-27 | Organic compositions to treat epas1-related diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019028972A Division JP2019089836A (ja) | 2013-02-28 | 2019-02-21 | Ｅｐａｓ１関連疾患を治療するための有機組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016511256A JP2016511256A (ja) | 2016-04-14 |
| JP2016511256A5 true JP2016511256A5 (enExample) | 2017-03-30 |
Family
ID=50483469
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560296A Withdrawn JP2016511256A (ja) | 2013-02-28 | 2014-02-27 | Ｅｐａｓ１関連疾患を治療するための有機組成物 |
| JP2019028972A Pending JP2019089836A (ja) | 2013-02-28 | 2019-02-21 | Ｅｐａｓ１関連疾患を治療するための有機組成物 |
| JP2021031732A Pending JP2021091710A (ja) | 2013-02-28 | 2021-03-01 | Ｅｐａｓ１関連疾患を治療するための有機組成物 |
| JP2023046940A Pending JP2023068147A (ja) | 2013-02-28 | 2023-03-23 | Ｅｐａｓ１関連疾患を治療するための有機組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019028972A Pending JP2019089836A (ja) | 2013-02-28 | 2019-02-21 | Ｅｐａｓ１関連疾患を治療するための有機組成物 |
| JP2021031732A Pending JP2021091710A (ja) | 2013-02-28 | 2021-03-01 | Ｅｐａｓ１関連疾患を治療するための有機組成物 |
| JP2023046940A Pending JP2023068147A (ja) | 2013-02-28 | 2023-03-23 | Ｅｐａｓ１関連疾患を治療するための有機組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9868949B2 (enExample) |
| EP (1) | EP2961843A2 (enExample) |
| JP (4) | JP2016511256A (enExample) |
| CN (1) | CN105247051A (enExample) |
| AU (3) | AU2014223432A1 (enExample) |
| CA (1) | CA2902393C (enExample) |
| HK (1) | HK1214301A1 (enExample) |
| SG (2) | SG10201706960TA (enExample) |
| WO (1) | WO2014134255A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201706960TA (en) * | 2013-02-28 | 2017-10-30 | Arrowhead Res Corp | Organic compositions to treat epas1-related diseases |
| WO2016196239A1 (en) * | 2015-05-29 | 2016-12-08 | Arrowhead Pharmaceuticals, Inc. | Compositions and methods for inhibiting gene expression of hif2alpha |
| WO2018102397A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| EP3784267B1 (en) | 2018-04-27 | 2025-11-12 | Arrowhead Pharmaceuticals, Inc. | Integrin targeting ligands and uses thereof |
| US20210093725A1 (en) | 2018-04-27 | 2021-04-01 | Arrowhead Pharmaceuticals, Inc. | Integrin targeting ligands and uses thereof |
| CA3120580A1 (en) * | 2019-01-09 | 2020-07-16 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use |
| CA3235013A1 (en) * | 2021-10-18 | 2023-04-27 | Jing Lu | Hypoxia inducible factor-2(alpha) inhibitors for the treatment of bladder cancer |
| WO2024102894A2 (en) * | 2022-11-11 | 2024-05-16 | The Regents Of The University Of California | Methods for treating monge's disease |
| CN119523991B (zh) * | 2024-12-06 | 2025-09-05 | 湖南师范大学 | 表木栓醇在制备抗肺癌物质中的用途和抗肺癌组合物 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5030453A (en) | 1983-03-24 | 1991-07-09 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
| US6977244B2 (en) | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| US5891467A (en) | 1997-01-31 | 1999-04-06 | Depotech Corporation | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
| EP2314700A1 (en) | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| WO2000053722A2 (en) | 1999-03-10 | 2000-09-14 | Phogen Limited | Delivery of nucleic acids and proteins to cells |
| US6309401B1 (en) | 1999-04-30 | 2001-10-30 | Vladimir Redko | Apparatus and method for percutaneous implant of a paddle style lead |
| EP1272630A2 (en) | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
| AU2001250572A1 (en) * | 2000-04-07 | 2001-10-23 | Epigenomics Ag | Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations |
| US6680068B2 (en) | 2000-07-06 | 2004-01-20 | The General Hospital Corporation | Drug delivery formulations and targeting |
| US20080188430A1 (en) | 2001-05-18 | 2008-08-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA) |
| WO2002100435A1 (en) | 2001-06-11 | 2002-12-19 | Centre Hospitalier Universitaire De Montreal | Compositions and methods for enhancing nucleic acid transfer into cells |
| EP1424998B1 (en) | 2001-08-16 | 2010-05-26 | The Trustees of The University of Pennsylvania | Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies |
| DE10230997A1 (de) | 2001-10-26 | 2003-07-17 | Ribopharma Ag | Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels |
| DE60334618D1 (de) | 2002-06-28 | 2010-12-02 | Protiva Biotherapeutics Inc | Verfahren und vorrichtung zur herstellung von liposomen |
| KR20050084607A (ko) | 2002-09-28 | 2005-08-26 | 매사추세츠 인스티튜트 오브 테크놀로지 | 인플루엔자 치료제 |
| US7655785B1 (en) * | 2002-11-14 | 2010-02-02 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
| US8090542B2 (en) * | 2002-11-14 | 2012-01-03 | Dharmacon Inc. | Functional and hyperfunctional siRNA |
| CA2506714A1 (en) | 2002-11-26 | 2004-06-10 | University Of Massachusetts | Delivery of sirnas |
| WO2004064731A2 (en) | 2003-01-14 | 2004-08-05 | University Of Washington | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymlplhoid tissues |
| CN101291653B (zh) | 2003-07-16 | 2012-06-27 | 普洛体维生物治疗公司 | 脂质包封的干扰rna |
| NZ545360A (en) | 2003-08-28 | 2009-06-26 | Novartis Ag | Interfering RNA duplex having blunt-ends and 3'-modifications |
| US8084599B2 (en) | 2004-03-15 | 2011-12-27 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| AU2005248147A1 (en) * | 2004-05-11 | 2005-12-08 | Alphagen Co., Ltd. | Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same |
| CN101346393B (zh) | 2005-11-02 | 2015-07-22 | 普洛体维生物治疗公司 | 修饰的siRNA分子及其应用 |
| EP2002004B1 (en) | 2006-03-23 | 2015-10-14 | Roche Innovation Center Copenhagen A/S | Small internally segmented interfering rna |
| GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
| CN101500548A (zh) | 2006-08-18 | 2009-08-05 | 弗·哈夫曼-拉罗切有限公司 | 用于体内递送多核苷酸的多缀合物 |
| US8314227B2 (en) | 2007-05-22 | 2012-11-20 | Marina Biotech, Inc. | Hydroxymethyl substituted RNA oligonucleotides and RNA complexes |
| ES2462416T3 (es) | 2007-08-06 | 2014-05-22 | Senju Pharmaceutical Co., Ltd. | Producto farmacéutico que contiene un inhibidor de la expresión de HIF-1 alfa y HIF-2 alfa |
| EP2238251B1 (en) | 2007-12-27 | 2015-02-11 | Protiva Biotherapeutics Inc. | Silencing of polo-like kinase expression using interfering rna |
| US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| US8067178B2 (en) | 2008-03-14 | 2011-11-29 | Genomic Health, Inc. | Gene expression markers for prediction of patient response to chemotherapy |
| DK2265283T3 (da) | 2008-03-18 | 2014-10-20 | Seattle Genetics Inc | Auristatin-lægemiddel-linker-konjugater |
| CN102037123A (zh) * | 2008-04-04 | 2011-04-27 | 卡兰多制药股份有限公司 | Epas1抑制剂的组合物和用途 |
| CN102325534B (zh) | 2008-12-18 | 2016-02-17 | 戴瑟纳制药公司 | 延长的dicer酶底物和特异性抑制基因表达的方法 |
| US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
| WO2011076807A2 (en) | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| SG183374A1 (en) | 2010-02-24 | 2012-09-27 | Arrowhead Res Corp | Compositions for targeted delivery of sirna |
| KR101223660B1 (ko) * | 2010-05-20 | 2013-01-17 | 광주과학기술원 | ＨＩＦ－２α 억제제를 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물 |
| CA2816155C (en) | 2010-12-17 | 2020-10-27 | Arrowhead Research Corporation | Galactose cluster-pharmacokinetic modulator targeting moiety for sirna |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| CA2822161C (en) | 2010-12-29 | 2018-05-29 | Philipp Hadwiger | Small molecule conjugates for intracellular delivery of nucleic acids |
| WO2012174224A2 (en) * | 2011-06-17 | 2012-12-20 | Calando Pharmaceuticals, Inc. | Methods for administering nucleic acid-based therapeutics |
| HK1199736A1 (en) | 2011-08-26 | 2015-07-17 | 箭头研究公司 | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
| WO2013158141A1 (en) | 2012-04-18 | 2013-10-24 | Arrowhead Research Corporation | Poly(acrylate) polymers for in vivo nucleic acid delivery |
| SG10201706960TA (en) * | 2013-02-28 | 2017-10-30 | Arrowhead Res Corp | Organic compositions to treat epas1-related diseases |
| US9504747B2 (en) | 2013-03-08 | 2016-11-29 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
-
2014
- 2014-02-27 SG SG10201706960TA patent/SG10201706960TA/en unknown
- 2014-02-27 WO PCT/US2014/018873 patent/WO2014134255A2/en not_active Ceased
- 2014-02-27 CN CN201480011225.5A patent/CN105247051A/zh active Pending
- 2014-02-27 HK HK16102257.6A patent/HK1214301A1/zh unknown
- 2014-02-27 US US14/770,765 patent/US9868949B2/en active Active
- 2014-02-27 AU AU2014223432A patent/AU2014223432A1/en not_active Abandoned
- 2014-02-27 SG SG11201506805QA patent/SG11201506805QA/en unknown
- 2014-02-27 EP EP14717233.2A patent/EP2961843A2/en active Pending
- 2014-02-27 CA CA2902393A patent/CA2902393C/en active Active
- 2014-02-27 JP JP2015560296A patent/JP2016511256A/ja not_active Withdrawn
-
2017
- 2017-12-07 US US15/834,323 patent/US10538765B2/en active Active
-
2019
- 2019-02-21 JP JP2019028972A patent/JP2019089836A/ja active Pending
-
2020
- 2020-01-21 US US16/747,729 patent/US11261444B2/en active Active
- 2020-03-04 AU AU2020201617A patent/AU2020201617A1/en not_active Abandoned
-
2021
- 2021-03-01 JP JP2021031732A patent/JP2021091710A/ja active Pending
-
2022
- 2022-05-23 AU AU2022203490A patent/AU2022203490A1/en not_active Abandoned
-
2023
- 2023-03-23 JP JP2023046940A patent/JP2023068147A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016511256A5 (enExample) | ||
| JP2015517466A5 (enExample) | ||
| JP2014525435A5 (enExample) | ||
| JP2015503608A5 (enExample) | ||
| US20200332300A1 (en) | Multi-target modulation for treating fibrosis and inflammatory conditions | |
| JP2013514321A5 (enExample) | ||
| EP3236945B1 (en) | Therapeutic compositions and methods for malignant tumors with rnai molecules targeted to hsp47 and p21 | |
| JP7627042B2 (ja) | Ｏ－メチルリッチ完全安定化オリゴヌクレオチド | |
| JP2023093644A (ja) | アンジオテンシノーゲンの発現を調節するための化合物及び方法 | |
| JP2019504112A5 (enExample) | ||
| JP2013525332A5 (enExample) | ||
| JP6944942B2 (ja) | ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療 | |
| WO2008109105A3 (en) | Methods and compositions for improved therapeutic effects with sirna | |
| JP7291418B2 (ja) | Ｐｃｓｋ９を標的としたアンチセンス核酸 | |
| HRP20201200T1 (hr) | OLIGONUKLEOTIDNI SPOJEVI ZA CILJANJE HUNTINGTIN mRNK | |
| JP2019506862A5 (enExample) | ||
| JP2019503199A5 (enExample) | ||
| JP7360705B2 (ja) | ｍｉＲＮＡを含むがん治療用医薬組成物 | |
| WO2011130458A3 (en) | Rna aptamers against baff-r as cell-type specific delivery agents and methods for their use | |
| JP2019529571A5 (enExample) | ||
| KR20230138462A (ko) | 암 치료를 위한 템플릿 지시된 면역조절 | |
| JP2014534229A5 (enExample) | ||
| JP2013530685A5 (enExample) | ||
| Tsang et al. | U1 adaptors suppress the KRAS-MYC oncogenic axis in human pancreatic cancer xenografts | |
| Claude-Taupin et al. | Use of epigenetic modulators as a powerful adjuvant for breast cancer therapies |